Reproductive hormones and cancer: Ovarian and colon cancer

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 3, 2002, Pages 527-540

  Burkman, Ronald T ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GONADOTROPIN; ORAL CONTRACEPTIVE AGENT;

APOPTOSIS; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; CONTRACEPTION; CORRELATION ANALYSIS; DRUG USE; FAMILY HISTORY; FEMALE; GENE MUTATION; GONADOTROPIN BLOOD LEVEL; HUMAN; OVARY CANCER; OVULATION INHIBITION; PARITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; UNITED STATES;

COLONIC NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 0036738435     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(02)00014-1     Document Type: Review

References (70)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
2. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-20.
3. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-8.
4. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692-5.
5. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
6. Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS. A case control study of carcinoma of the ovary. Br J Prev Soc Med 1977;31:148-53.
7. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet 1979;2:170-3.
8. Hildreth NG, Kelsey JL, LiVolsi VA, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981;114:398-405.
9. Willett WC, Bain C, Hennekens CH, Rosner B, Speizer FE. Oral contraceptives and risk of ovarian cancer. Cancer 1981;48:1684-7.
10. Ramcharan S, Pellegrin FA, Ray R, Hsu JP. The Walnut Creek Contraceptive Study: a prospective study of the side effects of oral contraceptives. NIH Publication 81-564. Bethesda, MD: National Institutes of Health; 1981.
11. Weiss NS, Lyon JL, LiffJM, Vollmer WM, Daling JR. Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 1981;28:669-71.
12. Rosenberg L, Shapiro S, Slone D, et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA 1982;247:3210-2.
13. Cramer DW, Hutchison GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 1982;307:1047-51.
14. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983;117:128-39.
15. La Vecchia C, Franceschi S, Decarli A. Oral contraceptive use and the risk of epithelial ovarian cancer. Br J Cancer 1984;50:31-4.
16. Tzonou A, Day NE, Trichopoulos D, et al. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 1984;20:1045-52.
17. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. BMJ 1987;294:1518-20.
18. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
19. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989;60:592-8.
20. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1989;18:538-45.
21. Parazzini F, La Vecchia C, Negri E, Bocciolone L, Fedele L, Franceschi S. Oral contraceptive use and the risk of ovarian cancer: an Italian case-control study. Eur J Cancer 1991;27:594-8.
22. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988; 48:5849-52.
23. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 1989;49:3670-4.
24. Badawy YA, Bayoumi DM. An epidemiologic study of ovarian cancer. Part 1: Reproductive and social factors. J Egypt Public Health Assoc 1992;67:465-77.
25. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type: results of a case-control study. Am J Epidemiol 1996;144:363-72.
26. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000;152:233-41.
27. Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol 1994;84:760-4.
28. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:235-40.
29. Wu ML, Whittemore AS, Paffenbarger Jr. RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988;128:1216-27.
30. Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract: results from the Royal College of General Practitioners' Oral Contraception Study. Lancet 1988; 2:1331-5.
31. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994;83:419-24.
32. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-6.
33. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990;43:559-68.
34. Simon WE, Albrecht M, Hansel M, Dietel M, Holzel F. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983; 70:839-45.
35. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-6.
36. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7.
37. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Pettersson KS, Huhtaniemi IT. Luteinizing hormone, its beta-subunit variant, and epithelial ovarian cancer: the gonadotropin hypothesis revisited. Am J Epidemiol 2001;154:43-9.
38. Sanderson M, Williams MA, Weiss NS, Hendrix NW, Chauhan SP. Oral contraceptives and epithelial ovarian cancer. Does dose matter? J Reprod Med 2000;45:720-6.
39. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-9.
40. Negri E, Tzonou A, Beral V, et al. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 1999;80:848-51.
41. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-75.
42. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
43. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
44. Kune GA. Causes and control of colorectal cancer: a model for cancer prevention. Boston: Kluwer Academic Publishers; 1996.
45. Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst 1981;67:57-60.
46. Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 1983;71:703-9.
47. Furner SE, Davis FG, Nelson RL, Haenszel W. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res 1989;49:4936-40.
48. Kune GA, Kune S, Watson LF. Oral contraceptive use does not protect against large bowel cancer. Contraception 1990;41:19-25.
49. Fernandez E, La Vecchia C, D'Avanzo B, Franceschi S, Negri E, Parazzini F. Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Br J Cancer 1996; 73:1431-5.
50. Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control 1994;5: 38-52.
51. Martinez ME, Grodstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:1-5.
52. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Aust 1995;162:491-3.
53. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998;7:653-9.
54. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
55. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-8.
56. Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 1999;8:1155-66.
57. Wu-Williams AH, Lee M, Whittemore AS, et al. Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 1991;51:2307-11.
58. Persson I. Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas 1996;23:S37-45.
59. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067-71.
60. Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni Jr. JF. A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes Control 1997;8:130-8.
61. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996;5:779-84.
62. Peipins LA, Newman B, Sandler RS. Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1997;6:671-5.
63. Jacobson JS, Neugut AI, Garbowski GC, et al. Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). Cancer Causes Control 1995;6:513-8.
64. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128:705-12.
65. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980;65:1201-7.
66. Everson GT, McKinley C, Kern Jr. F. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991;87:237-46.
67. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7:536-40.
68. Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJ. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res 1994;14:1037-41.
69. Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992;12:1327-30.
70. Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251-8.